Is there a generic for Chlorotrianisene?

Yes. The FDA Orange Book lists 1 approved generic (ANDA) application for Chlorotrianisene, referencing the brand TACE. Generics rated with an "A" therapeutic-equivalence code are considered substitutable for the brand.

What is the reference-listed drug for Chlorotrianisene?

TACE (NDA 008102, SANOFI AVENTIS US) is the reference-listed drug — the approved product a generic applicant must show its version is the same as.

What dosage forms of Chlorotrianisene are approved?

Chlorotrianisene is approved in the following dosage form: capsule.

FDA Orange Book · active-ingredient family

Chlorotrianisene

Chlorotrianisene is approved as 3 brand and 1 generic application in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:TACE · NDA 008102

Brand (NDA)

Generics (ANDA)

Listed patents

Exclusivity periods

Brand (NDA) products · capsule

Product	Applicant	Application	TE	Approved
TACE	SANOFI AVENTIS US	NDA 008102	—	Approved Prior to Jan 1, 1982
TACE	SANOFI AVENTIS US	NDA 011444	—	Approved Prior to Jan 1, 1982
TACE	SANOFI AVENTIS US	NDA 016235	—	Approved Prior to Jan 1, 1982

Generic (ANDA) products (1)

Product	Applicant	Application	TE	Approved
CHLOROTRIANISENE	BANNER PHARMACAPS	ANDA 084652	—	Approved Prior to Jan 1, 1982

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Chlorotrianisene — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.

Book a Demo